Artivion price target lowered to $48 from $51 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Artivion (AORT) to $48 from $51 and keeps a Buy rating on the shares. The firm said Artivion reported a very strong Q4 that was somewhat masked by a one-time revenue reduction to settle a $2.3M payment to the Italian government. Management issued guidance at the midpoint which contemplates low 20% growth in aortic stent grafts, mid-teens growth in On-X, MSD growth in BioGlue and no growth in tissue services.